反応式
[C:1]([O:5][C:6]([NH:8][C@H:9]([C:14]([OH:16])=O)[CH2:10][CH2:11][S:12][CH3:13])=[O:7])([CH3:4])([CH3:3])[CH3:2].Cl.[CH2:18]([O:20][C:21](=[O:25])[CH2:22][CH2:23][NH2:24])[CH3:19].C([O-])([O-])=O.[K+].[K+]>CN(C=O)C.N1C=CC=CC=1.CN(C1C=CN=CC=1)C.C([O-])(O)=O.[Na+]>[CH3:4][C:1]([CH3:2])([O:5][C:6]([NH:8][CH:9]([CH2:10][CH2:11][S:12][CH3:13])[C:14]([NH:24][CH2:23][CH2:22][C:21]([O:20][CH2:18][CH3:19])=[O:25])=[O:16])=[O:7])[CH3:3]参加物
8
反応物 3
生成物 1
試薬・触媒・溶媒 4
実験手順
A solution of N-(tert-butoxycarbonyl)-L-methionine (6.2 g) in DMF (25 ml) and pyridine (25 ml) was treated with DSC (9.6 g) and a catalytic amount of DMAP. After 4 hours, a solution of β-alanine ethyl ester HCl (3.8 g) and K2CO3 (3.5 g) in saturated aqueous NaHCO3 (25 ml) was added. The reaction mixture was stirred overnight at room temperature. The excess solvent was removed under reduced pressure and purified by HPLC (RP--CH3CN/H2O). N-[2-[[(1,1-dimethylethoxy)carbonyl]-amino]-4-(methylthio)-1-oxobutyl]-β-alanine, ethyl ester (7.0 g) as a colorless oil was obtained. The oil was confirmed as the desired product by MS and used without further purification.
後処理
- customThe excess solvent was removed under reduced pressure
- custompurified by HPLC (RP--CH3CN/H2O)
出典と根拠
- ORDレコード
- ord-432072e6407141fb8de154a6a1b3c967
- 出典データセット
- uspto-grants-2000_02
- 特許番号
- US06028223
関連ノート
読み込み中…